1034895-42-5

1034895-42-5 structure

Name: 9-ING-41
Chemical Name: 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione
CAS Number: 1034895-42-5
Molecular Formula: C₂₂H₁₃FN₂O₅
Molecular Weight: 404.34700
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2018-12-01 18:02:51
Modify Date: 2024-01-22 15:26:56
9-ING-41 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor[1]. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β. 9-ING-41 has anticancer activity[2].

Name	3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-1H-pyrrole-2,5-dione
Synonyms	9-ING-41 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione 3-(5-fluoro-benzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-pyrrole-2,5-dione

Description	9-ING-41 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor[1]. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β. 9-ING-41 has anticancer activity[2].
Related Catalog	Signaling Pathways >> Stem Cell/Wnt >> GSK-3 Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> PI3K/Akt/mTOR >> GSK-3
Target	GSK-3β
In Vitro	9-ING-41 (2, 4 μM; 48 hours) decreases neuroblastoma cell viability induces apoptosis[2]. 9-ING-41 (1, 2 μM; 24 hours) is a potent cell cycle-blocking agent for lymphoma cells[2]. 9-ING-41 (0.1-1 µM) inhibits GSK-3 leading to a decreased expression of the NF-κB target XIAP and significant apoptosis in neuroblastoma cells as shown by PARP cleavage, an apoptosis marker[1]. 9-ING-41 (0.5, 1.0, 1.5, 2.0 μM) inhibits the proliferation rate of all TCL and MCL lines with concentrations as low as 1.0 mM[2]. Cell Viability Assay[2] Cell Line: TCL and MCL lines Concentration: 2, 4 μM Incubation Time: 48 hours Result: Induced apoptosis. Cell Cycle Analysis[2] Cell Line: Lymphoma cells (Jeko, Mino, and OCI-Ly cell lines) Concentration: 1, 2 μM Incubation Time: 24 hours Result: Led to cell cycle arrest in G2/M. Western Blot Analysis[1] Cell Line: SK-N-DZ and SK-N-BE neuroblastoma cells Concentration: 0.1, 1 µM Incubation Time: 48 hours Result: Inhibited GSK-3 leading to a decreased expression of the NF-κB target XIAP.
In Vivo	9-ING-41 (40 mg/kg/every other day; for 17 days) has single-agent antitumor activity in a mouse model of MCL[2]. Animal Model: NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice[2] Dosage: 40 mg/kg Administration: Every other day; for 17 days Result: Had single-agent antitumor activity in a mouse model of MCL.
References	[1]. Ugolkov AV, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29(8):717-724. [2]. Wu X, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019 Jul 25;134(4):363-373.

Molecular Formula	C₂₂H₁₃FN₂O₅
Molecular Weight	404.34700
Exact Mass	404.08100
PSA	82.70000
LogP	3.68830
Storage condition	-20°C

1034895-42-5	90880-23-2
99658-03-4	89374-78-7
92973-65-4	89374-81-2
183170-02-7	793-39-5
79299-77-7	379-81-7
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	930439-75-1
1018584-77-4	1375289-11-4
849349-65-1	127437-46-1